Cytochrome P450 and drug interactions

Indian Journal of Pharmacology

Volumn 33, Issue 4, 2001, Pages 248-259

  Badyal, D K ^a   Dadhich, A P ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Cytochrome P450; Drug interactions; Isoenzymes

Indexed keywords

ANTIFUNGAL AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CIMETIDINE; CIPROFLOXACIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DILTIAZEM; DRUG; FLUOXETINE; HORMONE; MACROLIDE; NIFEDIPINE; PAROXETINE; PHENYTOIN; PROPOFOL; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG; VERAPAMIL;

AGE; BIOTRANSFORMATION; DRUG ANTAGONISM; DRUG METABOLISM; DRUG POTENTIATION; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME ISOLATION; ENZYME KINETICS; ENZYME LOCALIZATION; ENZYME REGULATION; GENDER; GENETIC POLYMORPHISM; HUMAN; IN VIVO STUDY; INFLAMMATION; LIVER; NONHUMAN; NUTRITION; PREGNANCY; REVIEW;

EID: 0034841255     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Interindividual variation in human liver cytochrome P450 enzymes involved in oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Causasians
2. P450 superfamily: Update on new sequence, gene mapping, accession numbers and nomenclature
3. Cytochrome P450 isozymes and antiepileptic drug interactions
4. In vitro interaction studies: Experience of the food and drug administration
5. A potentially hazardous interaction between erythromycin and midazolam
6. Drug interactions with quinolones
7. Midazolam hydroxylation by human liver misrosomes in vitro: Inhibition by fluoxetine, norfluoxetine and azole antifungals
8. In vitro and in vivo drug interactions involving CYP3A
9. P450 enzymes: Inhibition mechanisms, genetic regulation and effect of liver disease
10. Pharmacokinetic drug interactions of macrolides
11. Influence of stiripentol on cytochrome P450 mediated metabolic pathway in humans: In vitro and in vivo comparison and calculation of in vivo inhibition constants
12. Mechanism based inactivation of human liver microsomal cytochrome P450IIIA4 by gestodene
13. Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism
14. Identification of glucocorticoid inducible cytochrome P450 in the intestinal mucosa of rats and man
15. Clinical pharmacokinetics of tacrolimus
16. Terfenadine metabolism in human liver: In vitro inhibition by macrolide antibiotics and azole antifungals
17. Triazolam is ineffective in patients taking rifampicin
18. Cisapride and fatal arrhythmia
19. Itraconazole increases plasma concentration of quinidine
20. Is QT interval prolongation harmful? A regulatory perspective
21. Plasma concentration and effect of oral methylprednisolone are considerably increased by itraconazole
22. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole
23. Itraconazole greatly increases plasma concentration and effect of felodipine
24. Pharmacokinetic drug interactions of vinca alkaloids: Summary of case reports
25. Effect of itraconazole on the pharmacokinetics of atorvastatin
26. Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences
27. Changes in pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin
28. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
29. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P4502D6
30. Effect of clarithromycin on cytochrome P-450: Comparison with other macrolides
31. The contribution of intestinal and hepatic CYP3A to interaction between midazolam and clarithromycin
32. Drug interactions
33. Inhibition of alprazolam and desimipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants
34. Inhibition by fluoxetine of cytochrome P4502D6 activity
35. Probable terfenadine-fluoxetine associated cardiac toxicity
36. The interaction of diltiazem with simvastatin
37. Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting
38. HIV-1 protease inhibitors: A review for clinicians
39. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam
40. Solvay's Luvox contraindication against co-administration with J and J Hismanal, MMD's Seldane prompts FDA review of other SSRI labelling
41. Metabolic interaction between mibefradil and HMG-CoA reductase: An in vitro and in vivo investigation in human liver preparation
42. Grapefruit juice-drug interactions
43. Effect of grapefruit juice on the pharmacokinetics of theophylline in healthy male volunteers
44. The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects
45. Effect of ciprofloxacin on the single dose pharmacokinetics of carbamazepine in rhesus monkeys
46. Drug interactions of gastrointestinal drugs
47. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study
48. Interactions of proton pump inhibitors with cytochrome P450: Consequences for drug interactions
49. The effect of rifampicin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive
50. Rifampicin induction of lidocaine metabolism in cultured human hepatocytes
51. Rifampicin reduces plasma concentration and effects of zolpidem
52. The effect of rifampicin on the pharmacokinetics of oral and intravenous ondansetron
53. Possible interaction between phenobarbitone, carbamazepine and itraconazole
54. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors
55. Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: The influence of dose and co-medication
56. Investigation of terbinafine as a CYP2D6 inhibitor in vivo
57. The oxidative metabolism of metoprolol in human liver microsomes: Inhibition by SSRIs
58. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6(CYP2D6) activity in human liver microsomes
59. The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine
60. Quinidine: Potent inhibitor of sparteine and debrisoquine oxidation in vivo
61. Nortriptyline intoxication induced by terbinafine
62. Variable disposition kinetics and electrocardiographic effect of flecainide during repeated dosing in humans: Contribution of genetic factors, dose-dependent clearance and interaction with amiodarone
63. Inhibition of melatonin metabolism and increased bioavailability of oral melatonin after fluvoxamine coadministration
64. Fluvoxamine inhibits the CYP2C19-catalysed bioactivation of chloroguanide
65. A fatal drug interaction between clozapine and fluoxetine
66. Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil and diltiazem therapy
67. Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy
68. Effect of calcium channel blockers on theophylline disposition
69. Theophylline N-demethylation as probes for P4501A1 and P4501A2
70. Impact of long term ethanol consumption on CYP1A2 activity
71. Metabolism of 4-(methylnitrosamine)-1-)3-pyridil-1-butanone(NNK) by human cytochrome P450 and its inhibition by phenethyl isothiocynate
72. Hydroxylation of warfarin by human cDNA-expressed cytochrome P450: A role of P4502C9 in the etiology of (S)-warfarin drug interactions
73. Adverse interaction between warfarin and natural remedies: Spontaneous case report in Sweden
74. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone
75. Genetic polymorphism of the hepatic cytochrome P4502C19 in north Indian subjects
76. Artemisinin induces omeprazole metabolism in human beings
77. Single dose disulfiram inhibits chlorzoxazone metabolism: A clinical probe for P4502E1
78. Acetaminophen activation by human liver cytochrome P450IIE1 and P4501A2
79. Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathological conditions
80. In vivo age related changes in hepatic drug oxidising capacity in humans
81. Quantification of 3-month intraindividual variations and influence of sex and menstrual cycle phases on CYP3A activity as measured by phenotyping with intravenous midazolam
82. Influence of menstrual cycle and gender on alprazolam pharmacokinetics
83. The pituitary-liver axis in human drug metabolism
84. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy
85. Validation of the five drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug metabolic enzymes
86. Genetic polymorphism of CYP2D6 in a Keralite (South India) population
87. Codeine test pain threshold to copper vapor laser stimuli in extensive but not in poor metabolisers of sparteine
88. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans
89. Cytochrome P450 and the individuality of species
90. Selective effect of liver disease on the activity of specific metabolising enzymes: Investigation of cytochrome P450 2C19 and 2D6
91. Acute-phase response, interleukin-6 and alteration of cyclosporin pharmacokinetics
92. Effect of fasting and obesity in humans on the 6-hydroxylation of chloroxazone: A putative probe of CYP2E1 activity
93. Induction of CYP2D6 in pregnancy
94. Specificity of substrate and inhibitor probes for cytochrome P450: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes
95. In vitro forecasting of drugs which may interfere with biotransformation of midazolam
96. Bantu Tanzanian have a decreased capacity to metabolise omeprazole and mephenytoin in relation to their CYP2C19 genotype
97. Combined phenotyping assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2 and xanthine oxidase with the "Cooperstown cocktail"
98. In vitro approaches to predicting drug interactions in vivo
99. Understanding consequences of concurrent therapies